La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Instil Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Instil Bio..

Instil Bio (NASDAQ:TIL) Azioni, Catena delle Opzioni

Instil Bio

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Instil Bio Inc

Till Capital Corp

Interface Inc

Listed Funds Trust Teucrium Agricultural Strategy No K-1 ETF

FlexShares Mornigstar US Market Factors Tilt Index Fund ETF

Earnings

News

Goldman Sachs Q4 Investment Banking Fees Rose 24% YoY, Global Banking & Markets Revenue Rose 33%, Provision For Credit Losses Fell 39%

D. Boral Capital analyst Jesse Sobelson maintains New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) with a Buy and maintains $2 price target.

Price Target

Analyst Ratings

HOVR

D. Boral Capital Maintains Buy on New Horizon Aircraft, Maintains $2 Price Target

Needham analyst Chris Pierce reiterates TrueCar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) with a Buy and maintains $5 price target.

Reiteration

TRUE

Needham Reiterates Buy on TrueCar, Maintains $5 Price Target

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Buy and maintains $9 price target.

CNTX

D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target

WIIM

Goldman Sachs shares are trading higher following better-than-expected Q4 financial results.

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has sustained <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">its bullish momentum</a> for the second consecutive day, driven by speculation around an XRP ETF and increasing whale transactions. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.76</td>
<td>$158.5 billion</td>
<td>+7.5%&nbsp;</td>
<td>+19%&nbsp;</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$96,664.83</td>
<td>$1.9 trillion</td>
<td>+0.2%&nbsp;</td>
<td>+1.6%&nbsp;</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,197.98</td>
<td>$385.4 billion</td>
<td>-0.5%&nbsp;</td>
<td>-4.5%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Cold Blooded Shiller described XRP as an "alive monster," predicting its ascent to $4.2 if the rally maintains momentum.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The <a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> monster is alive. Pushing against the highs, won&#39;t be long before this breaks and continues it&#39;s ascent upward. $4.20. <a href="https://t.co/srLuW0zF2T">https://t.co/srLuW0zF2T</a> <a href="https://t.co/oOk0X8Jcko">pic.twitter.com/oOk0X8Jcko</a>
&mdash; Cold Blooded Shiller (@ColdBloodShill) <a href="https://twitter.com/ColdBloodShill/status/1879458140808524140?ref_src=twsrc%5Etfw">January 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto trader Satoshi Flipper suggested XRP is on the verge of price discovery, indicating the potential for new highs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">PRICE DISCOVERY FOR <a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> LOADING <a href="https://t.co/BQXCcZawgW">pic.twitter.com/BQXCcZawgW</a>
&mdash; Satoshi Flipper (@SatoshiFlipper) <a href="https://twitter.com/SatoshiFlipper/status/1879479514813927862?ref_src=twsrc%5Etfw">January 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: Santiment data highlighted by crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1879457747537670249">shows</a> transactions over $1 million surged to 341 in the last 24 hours.
Coinglass reported XRP futures open interest reached $6 billion (as of Jan. 15), marking an 18% daily increase, the highest since December.
Derivatives trading volume rose 25%, while XRP spot inflows hit $99.3 million, a record high since Dec. 1, 2024.
Community News: David Gokhshtein, founder of Gokhshtein Media, <a href="https://x.com/davidgokhshtein/status/1879352526119850390">acknowledged</a> the rally, stating XRP holders "deserve" this momentum.
Omni Foundation co-founder Austin King <a href="https://x.com/0xASK/status/1879364677316321362">shared</a> insights into Ripple&#8217;s broader vision, beyond the anticipated XRP ETF launch in 2025:
<ul>
<li>Ripple plans to expand its fast, low-cost payment solutions to attract customers from traditional finance.</li>
<li>The company has processed over $50 billion in payments and aims to position the XRP Ledger as the hub for tokenizing global financial assets.</li>
</ul>
Jan. 15 marks the SEC's deadline to file an opening brief in its appeal against Judge Torres' ruling. 
Speculation remains over whether the SEC will contest XRP's classification as a security in programmatic sales.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42985959/xrp-up-16-in-7-days-could-it-temporarily-flip-ethereum-or-even-bitcoin">XRP Up 16% In 7 Days: Could It Temporarily Flip Ethereum Or Even Bitcoin?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

XRP Price Surges Another 7.5%: What Is Going On?

Macro Notification

General

Goldman Sachs Gr Q4 2024 GAAP EPS $11.95 Beats $8.30 Estimate, Sales $13.87B Beats $12.391B Estimate

HC Wainwright &amp; Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Buy and maintains $36 price target.

RGNX

HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $36 Price Target

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Hold to Hold.

PATH

Needham Reiterates Hold on UiPathto Hold

Jones Trading analyst Jason Weaver maintains GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) with a Buy and raises the price target from $32 to $55.

Jones Trading Maintains Buy on GEO Group, Raises Price Target to $55

Evercore ISI Group analyst James West downgrades NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) from Outperform to In-Line and lowers the price target from $25 to $18.

Downgrades

Evercore ISI Group Downgrades NOV to In-Line, Lowers Price Target to $18

Needham analyst Scott Berg reiterates Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Buy and maintains $20 price target.

FRSH

Needham Reiterates Buy on Freshworks, Maintains $20 Price Target

ALTS

ALT5 Sigma Inks Partnership With Hashtag Influencer To Enhance The Influencer Marketing Landscape By Enabling Influencers In The Gig Economy

Evercore ISI Group analyst James West downgrades Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) from Outperform to In-Line and lowers the price target from $62 to $44.

Evercore ISI Group Downgrades Schlumberger to In-Line, Lowers Price Target to $44

William Blair analyst Andrew Jeffrey initiates coverage on SoFi Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Outperform rating.

Initiation

SOFI

William Blair Initiates Coverage On SoFi Techs with Outperform Rating

OPTN

OptiNose Reveals Q4 Preliminary Results: Registers Revenues Of $22.4M Is In Line With Prior Guidance And Growth In XHANCE Prescriptions

On Wednesday, mid-tier gold miner IAMGOLD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) announced production of 667,000 ounces in 2024, marking a 43% increase from the previous year. This performance met its revised guidance at a mid-point, owing to strong production at the Essakane mine in Burkina Faso and the Westwood and Côté Gold mine in<a target="_blank" href="https://www.benzinga.com/topic/canada" rel="noreferrer noopener"> Canada</a>.
Essakane was the top producer, contributing 409,000 attributable ounces. While head grades decreased slightly in the latter half of the year, planned waste stripping positioned the mine for stable 2025 production of 360,000–400,000 ounces.
The Westwood complex in southwestern Québec also exceeded expectations, producing 134,000 ounces and surpassing its guidance of 115,000–130,000 ounces.
Côté Gold, which poured its first gold on March 31, contributed 124,000 attributable ounces, as CEO Renaud Adams<a target="_blank" href="https://www.iamgold.com/English/investors/news-releases/news-releases-details/2025/IAMGOLD-Announces-Preliminary-2024-Operating-Results--2025-Guidance/default.aspx" rel="noreferrer noopener"> called</a> the ramp-up "among the quickest" for a large-scale open-pit mine in Canada. Despite operational challenges, including a conveyor belt failure in December, the plant achieved several milestones, with periods of throughput exceeding nameplate capacity.
IAMGOLD aims to stabilize operations in 2025, with Côté expected to double production to 250,000–280,000 ounces attributable by year-end as the mine targets its full design throughput of 36,000 tons per day.
Côté's output is the primary driver for higher expectations for 2025, set for 735,000–820,000 ounces. The company anticipates all-in-sustaining costs (AISC) of $1,625–$1,800 per ounce, with costs decreasing in the second half of the year as Côté achieves greater efficiency.
Naturally, Côté will be the firm's exploration focus in 2025. Out of the $38 million budget, $13 million will go to Côté's resource conversion and district-wide exploration. The rest will serve to further drill at Essakane and advance the Nelligan project, which sits in the historic Chibougamau camp in Québec.
Despite a relatively low debt-to-equity ratio of 24.5%, IAMGOLD manages capital expenditures carefully, including $290 million in sustaining capital and $20 million in expansion projects.
Key projects include installing an additional secondary crusher at Côté Gold and continued development at Westwood and Essakane.
After a successful 2024, IAMGOLD is ready for more of the same. With Côté's advancement and strategic domestic exploration, the firm is well-positioned for growth toward one million ounces in attributable annual production within this decade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/01/42984708/b2gold-meets-2024-guidance-cuts-dividend-to-fuel-growth-plans" target="_blank" rel="noreferrer noopener">B2Gold Meets 2024 Guidance, Cuts Dividend To Fuel Growth Plans</a></li>
</ul>
Image via Shutterstock

Guidance

Commodities

Markets

IAMGOLD Achieves 43% Increase In 2024 Production, Targets Domestic Growth In 2025

Needham analyst Scott Berg reiterates Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) with a Buy and maintains $55 price target.

Needham Reiterates Buy on Sprout Social, Maintains $55 Price Target

William Blair analyst Andrew Jeffrey initiates coverage on Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Outperform rating.

AFRM

William Blair Initiates Coverage On Affirm Holdings with Outperform Rating

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</h3>
<ul>
<li>Dividend Yield: 5.57%</li>
<li>TD Cowen analyst Robert Moskow maintained a Hold rating and cut the price target from $34 to $32 on Jan. 8, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Evercore ISI Group analyst David Palmer downgraded the stock from Outperform to In-Line and lowered the price target from $38 to $35 on Jan. 7, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Oct. 30, Kraft Heinz posted third-quarter earnings of 75 cents per share, beating estimates, but reported a revenue decline and anticipates a prolonged recovery in U.S. retail.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">KHC news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/8218ab9a-9e7e-4522-8375-228aba88a427" alt="" style="width:579px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)</h3>
<ul>
<li>Dividend Yield: 5.37%</li>
<li>JP Morgan analyst Ken Goldman maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 3, 2025. This analyst has an accuracy rate of 77%.</li>
<li>B of A Securities analyst Bryan Spillane maintained a Neutral rating and cut the price target from $31 to $29 on Dec. 20, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Dec. 19, the company reported second-quarter adjusted earnings per share of 70 cents, beating the analyst consensus estimate of 67 cents.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">CAG news</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/14824195-75d1-4a55-84bb-390b41a774b5" alt="" style="width:652px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Cal-Maine Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>)</h3>
<ul>
<li>Dividend Yield: 3.89%</li>
<li>Goldman Sachs analyst Adam Samuelson maintained a Sell rating and raised the price target from $47 to $52 on July 17, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Stephens &amp; Co. analyst Ben Bienvenu reiterated an Equal-Weight rating with a price target of $65 on April 3, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On Jan. 7, Cal-Maine Foods reported better-than-expected quarterly EPS and revenues.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">CALM news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15071438/image-97.png" alt="" class="wp-image-734513" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15071438/image-97.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15071438/image-97-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15071438/image-97-768x699.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/42992639/how-to-earn-500-a-month-from-state-street-stock-ahead-of-q4-earnings">How To Earn $500 A Month From State Street Stock Ahead Of Q4 Earnings</a></li>
</ul>

Dividends

Pre-Market Outlook

Trading Ideas

CALM

Wall Street's Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields

17:04 EST Instil Bio (TIL) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Instil Bio files $200M mixed securities shelf

In a report released today, Reni Benjamin from JMP Securities reiterated a Hold rating on Instil Bio (TIL – Research Report). The company's shares ...

Instil Bio (TIL) Gets a Hold from JMP Securities

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio (TIL – Research Report) today and set a price target of $110.00. Mitc...

Instil Bio Poised for Growth Amid Biopharmaceutical Sector Activity and Strong Financial Position

H.C. Wainwright lowered the firm's price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 report. The ...

Instil Bio price target lowered to $110 from $120 at H.C. Wainwright

Merck to buy rights to Chinese cancer drug for up to $3.3B

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Instil Bio (TIL – Research Report). The associated price target rema...

Strategic Acquisitions and Market Potential Position Instil Bio's SYN-2510 as a Buy with High Growth Prospects

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Instil Bio ( ($TIL) ) has shared an announcement. Instil Bio, Inc., through its subsidiary Complex Therapeutics LLC, has secured an $85.6 million t...

Instil Bio Secures Loan to Refinance Facility

Jefferies upgraded Instil Bio (TIL) to Buy from Hold with a price target of $52, up from $11. Published first on TheFly – the ultimate source for r...

Instil Bio upgraded to Buy from Hold at Jefferies

Instil Bio (TIL)y announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco Biopharmaceuticals. ImmuneOnco announced...

Instil Bio announces clinical progress in China for IMM2510/SYN-2510

BNTX

SMMT

Press Releases

Instil Bio Announces Strategic Update

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Health Care

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Comments

Instil Bio

Instil Bio (TIL) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO